Prostate cancer tumors harboring BRCA1/2 mutations are exceptionally sensitive to PARP inhibitors, while genomic alterations in other DNA damage response (DDR) genes are less responsive. To identify previously unknown genes ...
Apr 4, 2023
0
4
Two key proteins linked to cell division can reliably predict disease recurrence in prostate cancer after radiotherapy treatment, according to new research.
Apr 4, 2023
0
37
The number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with ...
Apr 3, 2023
0
8
A rapid genetic testing model for patients with advanced prostate cancer can more quickly identify those with "actionable" gene variants eligible for newer targeted therapies, reports a clinical trial in The Journal of Urology.
Mar 29, 2023
0
3
A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.
Mar 28, 2023
0
17
A quick, affordable diagnostic test developed by a Washington State University researcher may help curb one of the most prevalent but least discussed sexually transmitted infections.
Mar 27, 2023
0
30
Detailed PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of lesions and may irradiate ...
Mar 24, 2023
0
5
Researchers at Sylvester Comprehensive Cancer Center and the Desai Sethi Urology Institute are pioneering research to harness machine learning for the diagnosis and prognosis of prostate cancer, using magnetic resonance imaging ...
Mar 24, 2023
0
14
An ongoing shortage of a drug for men with advanced prostate cancer is causing some patients to miss months of potentially life-extending treatment.
Mar 21, 2023
0
4
TALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.
Mar 17, 2023
0
6
